Dr. Gideon Blumenthal (Pt 1): The Journey into Working for the FDA on Cancer Treatment Regulation
07/17/19 • 24 min
Drs. Gideon Blumenthal & Jack West discuss his early career interests and trajectory from medical oncology training at the NIH to joining the Federal Drug Administration (FDA) to regulate oncology drugs.
Drs. Gideon Blumenthal & Jack West discuss his early career interests and trajectory from medical oncology training at the NIH to joining the Federal Drug Administration (FDA) to regulate oncology drugs.
Previous Episode
Dr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical Review
Dr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC.
Next Episode
Dr. Gideon Blumenthal (Pt 2): Working to Balance Access, Efficacy, and Safety at the FDA
Dr. West questions Dr. Gideon Blumenthal of the FDA about how he and his team there struggle to provide timely access to emerging cancer treatments, while also debating questions of the proper thresholds for efficacy and safety.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/the-beacon-126567/dr-gideon-blumenthal-pt-1-the-journey-into-working-for-the-fda-on-canc-6326746"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to dr. gideon blumenthal (pt 1): the journey into working for the fda on cancer treatment regulation on goodpods" style="width: 225px" /> </a>
Copy